Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis
| Autor: | J. E. Hoppe, H. J. Hagedorn, Anna Kraminer-Hagedorn, U. Halm |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Microbiology (medical)
Male Bordetella pertussis medicine.medical_specialty Sulfamethoxazole medicine.drug_class Whooping Cough Antibiotics Erythromycin Gastroenterology Trimethoprim Internal medicine Nasopharynx Trimethoprim Sulfamethoxazole Drug Combination medicine Humans Prospective Studies Child Whooping cough biology business.industry Erythromycin Ethylsuccinate Infant General Medicine biology.organism_classification medicine.disease Anti-Bacterial Agents Drug Combinations Infectious Diseases Anesthesia Child Preschool Vomiting Female medicine.symptom business medicine.drug |
| Zdroj: | Infection. 17(4) |
| ISSN: | 0300-8126 |
| Popis: | Fifty-five ambulatory children with early culture-proven pertussis were treated for two weeks either with erythromycin ethylsuccinate (n = 28) (50-80 mg/kg/day in three doses during meals) or with co-trimoxazole (n = 27) (6-10 mg trimethoprim/kg/day in two doses after meals). After completion of treatment, all patients in the erythromycin group were culture-negative, while in the co-trimoxazole group one child was still culture-positive. In this case vomiting may have played a role. Both agents appear to be able to eradicate Bordetella pertussis from the nasopharynx of patients with early whooping cough. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink